Clinical Trial Update: Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating methionine in patients with pulmonary alveolar proteinosis caused by MARS gene mutations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Alveolar Proteinosis

Drugs mentioned

• Methionine (L-methionine)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Pulmonary Alveolar Proteinosis, Mutation Ala393Thr of the MARS Gene | Phase 1, Phase 2 | Status: COMPLETED